0001193125-15-244486.txt : 20150702 0001193125-15-244486.hdr.sgml : 20150702 20150702173002 ACCESSION NUMBER: 0001193125-15-244486 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150630 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20150702 DATE AS OF CHANGE: 20150702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 15971127 BUSINESS ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: NATL INST FOR BIOPROCESSING RESEARCH STREET 2: FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK CO. DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 8-K 1 d75172d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

June 30, 2015

Date of report (Date of earliest event reported)

 

 

Nexvet Biopharma

public limited company

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Ireland   001-36828   98-1205017

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

National Institute for Bioprocessing Research and Training

Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland

(Address of principal executive offices, including Zip Code)

+353 (1) 901 0339

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 30, 2015, Graeme Wald resigned from the board of directors (the “Board”) of Nexvet Biopharma public limited company (the “Company”), including as a member of the audit committee of the Board. Mr. Wald’s resignation was not related to any disagreement or dispute with the Company. A copy of the resignation letter from Mr. Wald dated June 30, 2015 is filed as Exhibit 99.1 hereto and incorporated herein by reference.

In connection with Mr. Wald’s resignation, the Board reconstituted the audit committee of the Board, which now consists of Ashraf Hanna, Cormac Kilty and Chris Brown.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

   

Description

99.1    Resignation letter from Graeme Wald dated June 30, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Nexvet Biopharma public limited company
By:

/s/ Mark Heffernan, Ph.D.

Name: Mark Heffernan
Its: Chief Executive Officer

Date: July 2, 2015

EX-99.1 2 d75172dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

30 June 2015

Dear Dr Gunn

As previously agreed to with Nexvet, my tenure on the Board comes to an end on 30 June 2015. I therefore tender my immediate resignation as a Director of Nexvet Ltd. As such I also step down from the company’s Audit and Risk Committee.

I have thoroughly enjoyed my tenure on the Board, having also chaired the Audit and Risk Committee for a period and assisted in shepherding the company through its re-domicile to Ireland and NASDAQ listing.

Please pass my thanks on to the other Directors (in particular Chris Brown) for their help and assistance.

I wish you, the Board and Nexvet all the best in their endeavours.

Regards

/s/ Graeme Wald

Graeme Wald

cc: Mark Heffernan, Ashraf Hanna and Geraldine Farrell